20 AI Healthcare Companies of 2025  

Shots: 

• AI is revolutionizing healthcare, reshaping drug discovery, protein design, and precision therapeutics. Companies are now tackling previously “undruggable” targets and moving treatments through development pipelines faster than ever 

• The AI in the healthcare market is exploding. From a valuation of $26.57B in 2024, it is projected to reach $505.59B by 2033, growing at a CAGR of 38.8%. This rapid expansion is fueled by strong investment, widespread adoption in biopharma and healthcare, and growing confidence in AI-driven innovation 

• This report showcases the 20 AI-powered healthcare companies of 2025, highlighting the platforms, collaborations, and technologies that are driving breakthroughs across drug discovery, biologics, RNA therapeutics, and precision medicine

20. Variational AI 

Founded Year: 2019 

• Variational AI is an AI-enabled drug discovery company that combines deep generative models with physical chemistry and biological data to support the design of novel small-molecule therapeutics. Variational’s approach aims to improve efficiency and predictive accuracy compared with traditional drug discovery methods 

• Its Enki platform integrates generative AI, machine learning, and biophysical modeling to generate, optimize, and prioritize candidate molecules. This approach enables research teams to progress from hypothesis to lead candidates more rapidly while improving predicted properties and developability 

• In Sep’25, Variational AI entered into a collaboration with Merck & Co. to apply the Enki platform for the design of small-molecule candidates targeting Merck’s selected programs. Under the terms of the agreement, Merck retains exclusive development and commercialization rights, with the partnership valued at up to approximately $349M in upfront and milestone payments

19. Ventus Therapeutics 

Founded Year: 2019 

• Ventus Therapeutics is a precision immunology company focused on the development of small-molecule therapeutics targeting challenging innate immune and inflammatory pathways 

• The company’s ReSOLVE platform integrates structural biology, computational chemistry, biophysics, and AI-enabled modeling to enhance the speed and accuracy of small-molecule drug discovery 

• In Oct’25, Ventus Therapeutics entered into a multi-year collaboration with Genentech to discover and optimize novel small-molecule therapeutics for major disease indications. Under the terms of the agreement, Ventus is eligible to receive upfront and milestone payments exceeding $460M, in addition to tiered royalties on net sales 

18. Algen Biotechnologies 

Founded Year: 2018 

• Algen Biotechnologies is a biotechnology company that integrates artificial intelligence, functional genomics, and CRISPR-based technologies to support the identification of novel therapeutic targets 

• The company’s AlgenBrain platform analyzes large-scale RNA perturbation data across diverse human cell types and applies tunable gene-modulation approaches to identify and validate causal disease drivers. These capabilities enable the prioritization of high-value targets across immunology, inflammation, and other complex disease areas 

• In Oct’25, Algen Biotechnologies announced a multi-target collaboration with AstraZeneca to develop gene-based therapies using its AI-enabled discovery platform. The agreement is valued at up to $555M and includes upfront payments, development milestones, and additional consideration 

17. PostEra 

Founded Year: 2019 

• PostEra is an AI-powered drug discovery company that applies machine learning and computational chemistry to support the design, optimization, and prioritization of small-molecule drug candidates. The company’s approach is intended to improve efficiency in navigating complex chemical space across early drug discovery programs 

• PostEra’s Proton platform is an end-to-end machine learning system focused on the chemistry of drug discovery. It integrates proprietary datasets with foundation models to design viable molecules, support reliable and efficient synthesis route planning, and apply active learning to generate informative experimental data, thereby reducing timelines across key stages of the discovery process 

• In Jan’25, PostEra expanded its drug discovery collaboration with Pfizer, increasing the total potential value of the partnership to $610M. The expanded collaboration supports the advancement of multiple programs, including small-molecule therapeutics and antibody–drug conjugates (ADCs) 
   

16. Formation Bio 

Founded Year: 2016 

• Formation Bio is an AI-enabled biopharmaceutical company that applies a combination of artificial intelligence tools to support drug development. The company’s model emphasizes the acquisition and in-licensing of promising clinical-stage assets, with the objective of advancing development programs more efficiently than traditional approaches 

• Its platform integrates AI-driven clinical trial design, real-world data analytics, centralized development operations, and capital-efficient portfolio management. These capabilities are intended to optimize study timelines, patient recruitment, and regulatory strategy across late-stage development programs 

• In Jun’25, Formation Bio reported that its subsidiary, Libertas Bio, licensed gusacitinib to Sanofi. Under the agreement, Sanofi plans to evaluate the asset in a new, previously unstudied indication through a P-I clinical study 

15. Absci 

Founded Year: 2011 

• Absci is an AI-native biotechnology company focused on the development of biologic therapeutics through de novo protein design. Rather than relying on traditional antibody discovery approaches, the company applies generative artificial intelligence to predict and design proteins intended for therapeutic use 

• The company’s technology integrates generative AI–based protein design with wet-lab synthetic biology, high-throughput screening, and automated data generation. Together, these capabilities support an end-to-end biologic drug creation process, from target concept through the optimization of antibody and protein therapeutics 

• In Aug’25, Absci expanded its collaboration with Almirall to accelerate the development of novel therapeutics for chronic and debilitating skin diseases. The expanded agreement carries a total potential value of approximately $650M 

14. Juvena Therapeutics 

Founded Year: 2018 

• Juvena Therapeutics is a computationally driven biopharmaceutical company focused on supporting tissue health by targeting endogenous regenerative signaling pathways. The company’s research centers on biological processes involved in muscle function, metabolic regulation, and age-related conditions 

• The company’s JuvNET platform integrates large-scale secreted-protein (secretome) mapping with multi-omic datasets and machine-learning models to identify functional protein regulators of tissue health. These capabilities support the discovery and prioritization of novel biologic drug candidates 

• In Jun’25, Juvena Therapeutics entered into a collaboration with Eli Lilly to advance therapies targeting muscle health. The agreement, valued at more than $650M, leverages Juvena’s AI-enabled discovery platform to identify biologic targets with translational potential 

13. Deep Apple Therapeutics 

Founded Year: 2022 

• Deep Apple Therapeutics is a biotechnology company that applies artificial intelligence, structural biology, and large-scale virtual compound libraries to support the discovery and design of novel small-molecule therapeutics. The company’s efforts are focused on addressing complex and historically challenging drug targets 

• Its discovery platform integrates deep learning with structural biology techniques, including cryo-electron microscopy, to analyze protein dynamics and explore expansive chemical space. These capabilities support the design and optimization of small-molecule drug candidates across complex disease areas 

• In Jun’25, Deep Apple Therapeutics entered into a collaboration with Novo Nordisk to discover and optimize oral small-molecule therapies for cardiometabolic diseases targeting a novel GPCR. Under the terms of the agreement, Deep Apple is eligible to receive up to $812M, including upfront payments, research funding, development milestones, and potential royalty components 

12. Nabla Bio 

Founded Year: 2020 

• Nabla Bio is a biotechnology company focused on AI-enabled protein design, developing custom antibodies and biologics intended to address complex and historically challenging drug targets. The company emphasizes de novo protein design, creating novel molecules from the atomic level rather than modifying existing structures 

• Its core technology, the Joint Atomic Model (JAM) platform, is a generative system that supports the design of new protein structures, including multispecific antibodies, receptor decoys, membrane-protein binders, and related biologic formats 

• In Oct’25, Nabla Bio entered into a multi-year research collaboration with Takeda to advance the AI-driven design of protein therapeutics. The partnership leverages the JAM platform and includes upfront funding in the double-digit million range, along with potential milestone payments exceeding $1B 

11. VantAI 

Founded Year: 2019 

• VantAI is an AI-driven biotechnology company focused on understanding and modulating protein–protein interactions to support the development of new therapeutic modalities. The company applies generative modeling approaches to analyze three-dimensional protein interaction networks and inform the design of molecules capable of modulating these interactions 

• The company’s platform includes the Neo-1 foundation model and the NeoLink structural proteomics system. Together, these technologies support the identification and validation of target–effector protein pairs for next-generation drug design, including proximity-based therapeutics such as molecular glues, degraders, and other proximity modulators 

• In Aug’25, VantAI entered into a strategic research collaboration with Halda Therapeutics to discover and develop next-generation RIPTAC (Regulated Induced Proximity Targeting Chimeras) medicines for oncology and immunology indications. The collaboration includes upfront payments, development milestones, and royalty components, with a total potential value exceeding $1B 

10. Creyon Bio 

Founded Year: 2019 

• Creyon Bio is an AI-driven biotechnology company focused on the development of RNA-targeted therapeutics. The company applies machine learning and large-scale biological datasets to address disease areas that may be challenging to treat using traditional drug discovery approaches 

• Its technology platform, NucleIQ, integrates AI-guided oligonucleotide design with RNA target discovery and high-throughput experimental validation. Together, these capabilities support the identification, optimization, and prioritization of RNA-targeted oligonucleotides across multiple disease areas 

• In Apr’25, Creyon Bio entered into a collaboration with Eli Lilly to accelerate the discovery and development of RNA-targeted oligonucleotide therapies across a range of indications. The partnership leverages Creyon Bio’s AI-enabled platform to support the expansion of Lilly’s RNA therapeutics pipeline and carries a total potential value of approximately $1.01B 

9. Generate:Biomedicines 

Founded Year: 2018 

• Generate:Biomedicines is a biotechnology company focused on the application of generative biology, using artificial intelligence and computational methods to design novel proteins for therapeutic development. The company’s approach centers on creating optimized biologics to address disease targets that may be challenging for traditional drug discovery methods 

• The company’s Generate Platform integrates machine learning with high-throughput experimental validation to support the design, construction, and testing of novel proteins, including antibodies, enzymes, and peptides 

• In Sep’24, Generate:Biomedicines entered into a multi-target collaboration with Novartis to co-discover and develop generatively designed protein therapeutics. Under the terms of the agreement, Generate received an upfront payment of $65M, including an equity component, and is eligible for over $1B in potential milestone payments, along with tiered royalty provisions 

8. Superluminal Medicines 

Founded Year: 2022 

• Superluminal Medicines is a biotechnology company applying artificial intelligence, structural biology, and protein dynamics to support the discovery of small-molecule therapeutics. The company’s approach is focused on addressing complex drug targets, including G protein–coupled receptors (GPCRs), which have historically presented challenges in small-molecule drug development 

• Its Hyperloop platform integrates AI and machine learning, structural and protein dynamics insights, predictive chemistry, and experimental validation to generate and optimize small-molecule candidates. The platform is applied primarily to cardiometabolic and metabolic disease programs with a focus on GPCR-driven biology 

• In Aug’25, Superluminal Medicines entered into a collaboration with Eli Lilly to advance small-molecule therapies for cardiometabolic diseases and obesity. The agreement includes upfront payments, equity investment, development milestones, and royalty components, with a total potential value of up to $1.3B  

7. Relation Therapeutics 

Founded Year: 2019 

• Relation Therapeutics is an AI-native biotechnology company focused on identifying the biological relationships underlying disease through data-driven approaches. The company aims to uncover novel therapeutic targets with stronger links to patient biology by integrating computational analysis with experimental validation 

• Its integrated Lab-in-the-Loop platform combines machine learning, large-scale multimodal biological data, functional genomics, and experimental validation to map disease networks, prioritize causal targets, and support early-stage drug discovery across multiple disease areas 

• In Dec’25, Relation Therapeutics entered into a target discovery collaboration with Novartis focused on identifying novel targets for atopic diseases. The multi-program collaboration leverages Relation’s AI-enabled platform and is valued at up to $1.75B, including upfront payments, development milestones, and potential royalty components 

6. Earendil Labs 

Founded Year: 2021 

• Earendil Labs is an AI-empowered biotechnology company focused on advancing drug delivery to the brain through the development of antibody-based therapies designed to cross the blood–brain barrier (BBB) and target neurological diseases 

• The company’s core technology, the HERMES platform, supports the design of bi-functional and bispecific antibodies capable of both BBB transcytosis and engagement of disease-relevant targets within the central nervous system. This platform is applied to the development of CNS-targeted biologics across neurodegenerative and rare neurological disorders 

• In Apr’25, Earendil Labs entered into a global licensing agreement with Sanofi covering two lead programs, HXN-1002 and HXN-1003, which are bispecific antibodies being developed for autoimmune and inflammatory bowel diseases. The agreement is valued at up to $1.84B and includes upfront payments as well as development and commercial milestone components 

5. insitro 

Founded Year: 2018 

• insitro is an AI-driven drug discovery company that integrates machine learning with large-scale human biology to investigate disease mechanisms and support the design of therapeutics with improved potential for clinical success. The company’s activities span target discovery, small-molecule design, and translational research 

• Its integrated technology platform combines ChemML for AI-guided small-molecule discovery with multimodal biological and phenotypic data generation, human genetics–anchored disease modeling, and high-throughput experimental and computational infrastructure. Together, these capabilities support end-to-end drug discovery, from causal biology to optimized drug candidates 

• In Oct’25, insitro extended its research collaboration with Bristol Myers Squibb, continuing the use of its ChemML platform to discover and optimize small-molecule therapies for a novel amyotrophic lateral sclerosis (ALS) target. The partnership includes potential milestone and royalty payments that could exceed $2B 

4. Manifold Bio 

Founded Year: 2019 

• Manifold Bio is a platform therapeutic AI company focused on addressing challenges associated with delivering therapeutics across the blood–brain barrier (BBB). The company develops programmable biologics designed to enable targeted delivery to the brain and specific cell types 

• Its platform integrates AI-driven protein engineering with high-throughput experimentation to design modular biologics, including BBB shuttle systems and targeted payload delivery technologies. These capabilities are intended to support the development of more effective treatments for neurological and neurodegenerative disorders 

• In Nov’25, Manifold Bio entered into a collaboration with Roche to develop next-generation BBB shuttle technologies for neurological and neurodegenerative indications. The partnership leverages Manifold Bio’s AI-enabled design platform to enhance brain delivery of biologic therapies and carries a total potential value exceeding $2.05B 

3. Orionis Biosciences 

Founded Year: 2015 

• Orionis Biosciences is a biotechnology company focused on the development of small-molecule therapeutics, with an emphasis on molecular glues designed to modulate disease-relevant protein interactions. The company’s work centers on expanding the functional capabilities of small molecules to address challenging biological targets 

• Orionis operates three core platforms: Allo-Glue, which supports AI-driven discovery and optimization of molecular glue therapeutics; the A-Kine Platform, designed to systematically generate and prioritize functional small molecules; and the MCE Cell Engager Platform, which enables engineered cellular models and target engagement assays to support mechanism validation and lead selection 

• In May’25, Orionis Biosciences entered into a multi-year collaboration with Genentech to identify and develop molecular glue therapies for oncology indications. The agreement included an upfront payment of $105M, with potential milestone and royalty payments that could exceed $2B 

2. Valo Health 

Founded Year: 2019 

• Valo Health is an AI-first technology company focused on integrating computation, biological data, and patient-derived insights to support drug discovery and development. The company’s approach emphasizes the use of data-driven methods to inform target identification and therapeutic development 

• Its Opal Computational Platform combines large-scale patient datasets, machine learning, and biological modeling to enable target discovery, drug design, and translational research across multiple therapeutic areas, including neurodegeneration, immunology, and oncology 

• In 2025, Valo Health entered into two significant collaborations with pharmaceutical partners. In Nov’25, the company signed a partnership valued at over $3B with Merck KGaA to advance the development of novel therapies for neurodegenerative disorders. Earlier, in Jan’25, Novo Nordisk expanded its collaboration with Valo Health to support the discovery and development of new therapies for cardiometabolic diseases, with a reported deal value of approximately $4.6B 

1. XtalPi  

Founded Year: 2015 

• XtalPi is an AI-driven platform company operating at the intersection of computational science, physics-based modeling, and experimental chemistry, supporting pharmaceutical companies in the discovery and development of small-molecule drugs. The company applies industrial-scale AI to address complex challenges across the drug development process 

• Its integrated platform combines AI algorithms, quantum physics–based simulations, cloud computing, and automated laboratory systems to enable molecule design, crystal structure prediction, solid-state development, and formulation optimization across multiple stages of the drug lifecycle 

• In Aug’25, XtalPi entered a multi-program drug discovery collaboration with Dovetree Medicines focused on the identification of novel therapeutics across several disease areas. The partnership is valued at ~$5.99B 

Sources:         

• Press releases       

• Company websites       

Currency Conversion: Oanda (£1 – $1.25, €1 – $1.04, kr.1 – 0.13, CHF 1 – 1.1; Dec 31, 2024)      

Criteria:  Companies are included based on the demonstrated scale and strategic significance of their AI platform–related partnerships and deals. The list features only fully AI-native companies and biotechnology firms where artificial intelligence is a core driver of discovery, development, or platform innovation. This is a curated, non-ranked list and does not imply comparative positioning or hierarchy among the featured companies.

Related Post: 20 Innovative Digital Therapeutics Companies of 2025